Abiomed, Inc.
IndexS&P 500 P/E85.60 EPS (ttm)2.96 Insider Own1.20% Shs Outstand45.51M Perf Week8.41%
Market Cap10.65B Forward P/E44.90 EPS next Y5.65 Insider Trans-10.38% Shs Float44.58M Perf Month-17.08%
Income136.50M PEG22.41 EPS next Q1.05 Inst Own95.40% Short Float2.52% Perf Quarter-12.62%
Sales1.03B P/S10.32 EPS this Y11.40% Inst Trans1.40% Short Ratio3.93 Perf Half Y-29.68%
Book/sh31.49 P/B8.06 EPS next Y24.41% ROA9.80% Target Price354.17 Perf Year-5.28%
Cash/sh15.95 P/C15.91 EPS next 5Y3.82% ROE10.90% 52W Range227.25 - 379.30 Perf YTD-29.34%
Dividend- P/FCF45.66 EPS past 5Y42.20% ROI12.50% 52W High-33.09% Beta1.40
Dividend %- Quick Ratio6.30 Sales past 5Y20.80% Gross Margin81.80% 52W Low11.68% ATR14.81
Employees1725 Current Ratio7.00 Sales Q/Q12.70% Oper. Margin14.10% RSI (14)39.67 Volatility5.52% 5.65%
OptionableYes Debt/Eq0.00 EPS Q/Q-26.40% Profit Margin14.50% Rel Volume0.97 Prev Close254.16
ShortableYes LT Debt/Eq0.00 EarningsApr 28 BMO Payout0.00% Avg Volume285.35K Price253.79
Recom2.50 SMA20-9.23% SMA50-14.80% SMA200-21.54% Volume291,730 Change-0.15%
Apr-06-22Initiated Wolfe Research Peer Perform $330
Jun-18-21Initiated Deutsche Bank Buy $360
Apr-27-20Downgrade SVB Leerink Outperform → Mkt Perform $175
Feb-12-20Downgrade Morgan Stanley Equal-Weight → Underweight $165
Feb-06-20Resumed BTIG Research Neutral
Oct-29-19Downgrade Raymond James Outperform → Mkt Perform
Aug-02-19Downgrade Morgan Stanley Overweight → Equal-Weight $325 → $215
Aug-02-19Downgrade Guggenheim Buy → Neutral
Aug-01-19Downgrade BTIG Research Buy → Neutral
Nov-07-18Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-02-18Upgrade BTIG Research Neutral → Buy
Jun-22-18Reiterated Piper Jaffray Overweight $360 → $480
Apr-04-18Initiated Goldman Buy $332
Jan-19-18Reiterated Leerink Partners Outperform $200 → $265
Oct-16-17Downgrade BTIG Research Buy → Neutral
Sep-29-17Initiated SunTrust Buy $195
Jun-08-17Resumed William Blair Outperform
Apr-06-17Upgrade Piper Jaffray Neutral → Overweight
Dec-07-16Initiated Guggenheim Buy
Oct-30-15Upgrade Raymond James Mkt Perform → Outperform
May-16-22 10:48AM  
May-12-22 09:45AM  
May-08-22 10:40AM  
May-02-22 08:37AM  
Apr-29-22 10:30AM  
Apr-28-22 08:52AM  
Apr-27-22 07:15AM  
Apr-26-22 08:02AM  
Apr-22-22 11:55AM  
Apr-21-22 10:35AM  
Apr-20-22 12:19PM  
Apr-19-22 11:44AM  
Apr-18-22 10:36AM  
Apr-14-22 10:29AM  
Apr-13-22 10:09AM  
Apr-12-22 10:46AM  
Apr-11-22 01:14PM  
Apr-08-22 10:00AM  
Apr-06-22 08:04AM  
Apr-05-22 07:46AM  
Apr-04-22 05:05PM  
Mar-29-22 09:33AM  
Mar-21-22 07:00AM  
Mar-16-22 11:51AM  
Mar-15-22 12:55PM  
Mar-12-22 10:45AM  
Mar-07-22 09:10AM  
Feb-11-22 10:55AM  
Feb-08-22 04:05PM  
Feb-03-22 01:09PM  
Jan-30-22 06:38AM  
Jan-28-22 09:19AM  
Jan-27-22 03:01PM  
Jan-24-22 11:32AM  
Jan-21-22 09:38PM  
Jan-20-22 12:10PM  
Jan-19-22 05:38PM  
Jan-14-22 07:00AM  
Jan-12-22 11:51AM  
Jan-11-22 05:20PM  
Jan-10-22 10:19AM  
Jan-07-22 04:41PM  
Jan-06-22 12:03PM  
Jan-05-22 01:38PM  
Jan-04-22 09:46AM  
Dec-30-21 09:40AM  
Dec-29-21 07:00AM  
Dec-16-21 04:26AM  
Dec-12-21 09:36PM  
Dec-06-21 11:15AM  
Nov-18-21 07:00AM  
Nov-04-21 08:05AM  
Nov-03-21 08:02AM  
Nov-01-21 07:58AM  
Oct-28-21 02:00PM  
Oct-25-21 03:27PM  
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the Automated Impella Controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; and Impella BTR, a percutaneous micro heart pump with integrated motors and sensors. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Trapp Todd AVICE PRESIDENT, CFOApr 04Sale333.001,000333,00013,063Apr 06 04:26 PM
Weber David MCHIEF OPERATING OFFICERMar 31Sale340.007,5002,550,000116,314Apr 04 05:07 PM
SUTTER MARTIN PDirectorFeb 17Sale314.714,0001,258,852130,390Feb 17 06:13 PM
Weber David MChief Operating OfficerFeb 16Sale325.007,5002,437,500123,814Feb 18 04:10 PM
SUTTER MARTIN PDirectorFeb 16Sale308.662,000617,322134,390Feb 17 06:12 PM
SUTTER MARTIN PDirectorFeb 15Sale303.652,000607,301136,390Feb 17 06:11 PM
Weber David MChief Operating OfficerFeb 09Option Exercise21.553,11267,064134,426Feb 09 05:43 PM
Weber David MChief Operating OfficerFeb 09Sale310.193,112965,311131,314Feb 09 05:43 PM
Weber David MChief Operating OfficerFeb 08Option Exercise21.557,413159,750138,727Feb 09 05:43 PM
Weber David MChief Operating OfficerFeb 08Sale302.907,4132,245,423131,314Feb 09 05:43 PM
Weber David MChief Operating OfficerFeb 07Option Exercise21.553006,465131,614Feb 09 05:43 PM
Weber David MChief Operating OfficerFeb 07Sale300.2530090,076131,314Feb 09 05:43 PM
Trapp Todd AVice President, CFOJan 05Sale359.431,000359,43014,063Jan 07 04:27 PM
SUTTER MARTIN PDirectorNov 18Sale338.5915,0005,078,787138,390Nov 18 04:45 PM
SUTTER MARTIN PDirectorNov 17Sale344.953,7501,293,573153,390Nov 18 04:45 PM
SUTTER MARTIN PDirectorNov 16Sale351.853,7501,319,448157,140Nov 18 04:45 PM
MINOGUE MICHAEL RChairman, President, CEOAug 23Option Exercise23.153,49280,840215,127Aug 25 04:37 PM
MINOGUE MICHAEL RChairman, President, CEOAug 23Sale350.003,4921,222,200211,635Aug 25 04:37 PM
THOMAS PAULDirectorAug 18Sale330.77663219,3016,908Aug 19 04:17 PM
SUTTER MARTIN PDirectorAug 18Sale332.903,7501,248,373161,890Aug 19 04:16 PM
SUTTER MARTIN PDirectorAug 17Sale326.733,7501,225,250165,640Aug 19 04:16 PM
MINOGUE MICHAEL RChairman, President, CEOAug 09Option Exercise23.157,037162,907218,672Aug 10 05:07 PM
MINOGUE MICHAEL RChairman, President, CEOAug 09Sale350.007,0372,462,950211,635Aug 10 05:07 PM
MINOGUE MICHAEL RChairman, President, CEOAug 06Option Exercise23.1524,471566,504236,106Aug 10 05:07 PM
MINOGUE MICHAEL RChairman, President, CEOAug 06Sale350.0024,4718,564,850211,635Aug 10 05:07 PM
MINOGUE MICHAEL RChairman, President, CEOAug 05Option Exercise23.1525,000578,750236,635Aug 06 04:16 PM
MINOGUE MICHAEL RChairman, President, CEOAug 05Sale341.1825,0008,529,582211,635Aug 06 04:16 PM
MINOGUE MICHAEL RChairman, President, CEOJun 21Option Exercise23.1525,000578,750236,635Jun 23 04:05 PM
MINOGUE MICHAEL RChairman, President, CEOJun 21Sale325.3525,0008,133,702211,635Jun 23 04:05 PM
SUTTER MARTIN PDirectorMay 19Sale267.443,7501,002,900169,010May 20 04:28 PM
SUTTER MARTIN PDirectorMay 18Sale266.723,7501,000,200172,760May 20 04:28 PM